HCT116 and HCT15 cells that highly express O 6 -methylguanine-DNA-methyltransferase (MGMT) displayed a transient cell cycle G2/M arrest in response to exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) alone; however, 70-80% of cells were arrested in G2/M after treatment with O 6 -benzylguanine (BG) and BCNU. Cells accumulated in G2/M showed elevated levels of an inactive form of cyclin B1/p-Cdc2 (Tyr15) complex that was not associated with activation of Chk1/p-Cdc25C and was independent of p53/p21 status. The most prominent feature of cell death was the appearance of enlarged and multinucleated cells that was related to the inhibition of mitotic entry. In contrast, BG-resistant cell lines, HCT116 BBR and HCT15 BBR cells that contain mutations K165E and K165N of MGMT, respectively, displayed a normal cell cycle progression with a slight and transient increase in G2/M arrest at 24 h after treatments with either BCNU alone or BG combined with BCNU. The differences in the ability to progress toward G2/M after treatment with BG and BCNU between cells expressing wild-type MGMT and mutated MGMT were confirmed in CHO cells transfected with human wild type and K165E mutant MGMT cDNA, respectively. Thus, our findings suggest that BG-inactivated MGMT may be linked to cell signaling events, forcing cells into a permanent G2/M arrest in response to the DNA damages induced by BCNU.
Introduction
The G2/M checkpoint is the most prominent effect of many anticancer agents in tumor cells when they have sustained DNA damages induced by therapeutic agents (Bunz et al., 1998; Andreassen et al., 2001; Deming et al., 2001) . G2/M arrest has been shown to be a protective mechanism that ensures orderly and timely repair of damages and prevents inappropriate mitotic entry (Hartwell and Weinert, 1989; Kaufmann and Paules, 1996) . Thus, tumor cell survival is dependent on an intact G2/M checkpoint after exposure to therapeutic DNA damaging agents (Hirose et al., 2001; Koniaras et al., 2001; Shah and Schwartz, 2001) . One of the network-complexes that regulate the G2 to M transition has now been revealed to be a Cdc25C-cyclin B1/Cdc2 controlled switch-like system. At the onset of mitosis, the complexes of cyclin B1/Cdc2 become active when the dual specificity phosphatase, Cdc25C, removes inhibitory phosphorylations on Cdc2. Once active the cyclin B1/Cdc2 complexes phosphorylate Cdc25C, which enhances its phosphatase activity (Hoffman et al., 1993; Peng et al., 1997; Aguda, 1999) . This autocatalytic feedback loop acts as a regulatory switch to control cell cycle progression from G2 into the mitosis phase until damaged DNA is repaired or DNA replication is completed. p53 induces the transcription of several proteins that regulate cell cycle progression. p21 appears to be induced in a p53-dependent manner after DNA damage and initiates cell cycle arrest by directly inhibiting the activity of cyclin dependent kinases. These proteins are also important for G2/M arrest after DNA damage (Kuerbitz et al., 1992; Xiong et al., 1993; Cox and Lane, 1995; Smits et al., 2000; Monte et al., 2003) . However, the signaling cascades controlling the G2/M checkpoint are much more complex and the inputs that sense the presence of DNA damage and initiate the G2/ M checkpoint still remain to be elucidated.
Cell cycle arrest has been generally thought to not be a manifestation of anticancer drug toxicity. It has become evident that tumor cells can be readily induced to undergo long-term growth arrest or proliferation arrest, as indicated by the apparent complete cessation of DNA replication and mitosis after treatment with chemotherapeutic drugs, radiation, or differentiating agents that leads to cell death (Campisi, 2001; Roninson, 2003) . Terminal growth arrest appears to be the principal tumor response to many chemotherapeutic agents such as doxorubicin, aphidicolin, cisplatin and cyclophosphamide; therefore, the reduction of terminal proliferation arrest becomes a novel phenotype of resistance to multiple DNA-interactive drugs (Wang et al., 1998; Chang et al., 1999a, b; Park et al., 2000) . Thus, long-term cell cycle arrest of tumor cells in response to DNA damage is considered as a determinant end point of drug-treatment response. The chemotherapeutic agent induced DNA damage checkpoint or permanent growth arrest may share the same druginduced genetic manipulations, which includes genes involved in regulation of cell growth, cell cycle checkpoint, DNA replication and mitosis, and genes involved in suppressing or promoting tumor growth (Chang et al., 1999a (Chang et al., , b, 2002 . However, the outcomes in response to therapeutic genotoxicity may be different: G2/M checkpoint leads to cell survival, whereas prolonged G2/M arrest causes cell death.
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is an alkylating chemotherapeutic agent. The chemical decomposition of BCNU forms reactive intermediate carbonium ions that bind to guanine at the O 6 -position in DNA to produce the monoadduct O 6 -chloroethylguanine. After intermolecular rearrangement, an intermediate O 6 ,N 1 -ethanoguanine is formed and actively reacts with the N3-position of cytosine on the opposite DNA strand to yield interstrand crosslinks. It is postulated that interstrand crosslinks are responsible for the killing effects of BCNU due to the ability to block DNA replication and to produce DNA doublestrand breaks (DSBs) during the replication of damaged DNA. The formation of these lethal lesions can be prevented by O 6 -methylguanine DNA methyltransferase (MGMT), which directs the repair of O 6 -chloroethylguanine resulting in the reduction of cell death induced by BCNU. O 6 -benzylguanine (BG), a potent inhibitor of MGMT, has been demonstrated to efficiently enhance BCNU-cytotoxicity through its ability to inactivate MGMT activity (Gibson et al., 1985; Pegg, 1990; Gerson et al., 1993; Liu et al., 1996) . Although we know a great deal about the chemical lesions produced by BCNU and their repair through MGMT, we still do not know much about the physiological response of cells to the DNA damage induced by the combination of BG with BCNU, such as how cell proliferation is regulated through the cell cycle checkpoints and how cells die or undergo apoptosis.
We have previously reported that combined treatments with BG and BCNU induced two different mutations at amino acid 165 in the MGMT gene in two mismatch repair-deficient colon cancer cell lines, HCT116 and HCT15, which were then named as HCT116 BBR and HCT15 BBR, respectively (Liu et al., 2002) . After acquiring a mutation at amino acid 165 of the MGMT gene, these cells became resistant to BG-induced inactivation of MGMT, leading to the failure of the potentiation of BCNU-cytotoxicity by BG; however, they maintained a similar sensitivity to BCNU alone when compared to their parental cells. In this study, we used these paired cell lines, HCT116 or HCT15 (expressing wild-type MGMT gene) and HCT116 BBR or HCT15 BBR (expressing mutant MGMT), to demonstrate that a differential regulation of G2/M arrest existed between cells expressing either wild-type MGMT or mutant MGMT after exposure to BG and BCNU, and that cell death induced by this combined treatment was associated with a prolonged G2/M arrest in cells expressing wild-type MGMT. We discuss the implications of these data on the possibility of MGMT in the signaling pathway to regulate BG and BCNU-induced G2/M arrest.
Results
Cells expressing wild-type MGMT permanently arrest in G2/M after treatment with BG plus BCNU To determine the role of BG-inactivated MGMT in the regulation of a cell cycle checkpoint in response to DNA damage induced by BCNU, we first asked whether BG alone was able to induce G2/M arrest. To address this question, HCT116 and HCT116 BBR cells were synchronized by serum starvation for 24 h and then treated with BG at concentrations of either 50 or 200 mM. Cells were harvested at different times for the analysis of cell cycle progression by flow cytometry. Results indicate that BG alone did not induce cell cycle arrest in these two cell lines and they displayed a very similar cell cycle progression. Results presented in Figure 1 show the cell cycle status at 24 h after treatment with BG alone for the comparison of cell cycle regulated by BG plus BCNU (Figure 2) . BG (at concentrations of both 50 and 200 mM) completely depleted MGMT activity in HCT116 cells but not in HCT116 BBR, in which MGMT activity remained at the same levels as untreated cells. Moreover, BCNU alone at a concentration of 50 mM had no effect on MGMT activity in these two cell lines (data not shown).
The effects of BCNU alone and BG plus BCNU were examined in relation to cell cycle arrest and levels of proteins that regulate the G2/M transition in HCT116 and HCT116 BBR cells. Cell cycle analysis revealed that without treatment, there was no significant difference in the proportion of each cell cycle phase between HCT116 and HCT116 BBR when grown in the exponential and asynchronous status. After treatment with BCNU alone (50 mM), a similar cell cycle regulation was noted in these two cell lines, in which B20% of cells underwent growth arrest in the G2/M transition at 24 h and then progressed through the transition to the next cell cycle Progression through G2/M requires cyclin B1/Cdc2 complexes. It has been shown that the activity of this complex is low through most of interphases, increases significantly before mitosis and then drops when mitosis begins (Hoffman et al., 1993; Peng et al., 1997) . We found that in HCT116 cells, prolonged G2/M arrest was accompanied by a concomitant increase in the expression of cyclin B1/p-Cdc2 (Tyr15) (Figure 3a) , which is an inactive form of this complex and a hallmark for G2/ M accumulation or mitotic delay (Lock, 1992; Poon et al., 1996; Kaufmann and Kies, 1998) . In contrast, the stabilized expression of cyclin B1/p-Cdc2 (Tyr15) was not observed in HCT116 BBR cells (Figure 3b ). These results demonstrate the differential G2/M checkpoint and expression of cyclin B1/p-Cdc2 (Tyr15) complex in response to the combined treatment with BG plus BCNU between cells expressing wt MGMT versus K165E MGMT. In comparison, after exposure to BCNU alone, the expression of cyclin B1/p-Cdc2 (Tyr15) in these two cell lines fluctuated similarly, that is, the levels of both proteins transiently increased at 4 and 24 h and decreased at 48 h, which was parallel with the transient G2 arrest. The total levels of Cdc2 displayed a similar pattern of expression to p-Cdc2 (Tyr15) through the cell cycle in these two cell lines.
To further test the possibility that inactivated MGMT by BG following treatment with BCNU contributed to a prolonged G2/M arrest, cell cycle checkpoint was also analysed in colon cancer cells, Vaco 8 (an MGMT deficient cell line) and Vaco 8/MGMT cells, in which wt MGMT gene is expressed by pCMV. As shown in Figure 4 , Vaco 8 cells (transfected with vector only) displayed an identical cell cycle regulation after exposure to either BCNU alone or BG plus BCNU, that is, only B20% of cells arrested in G2/M but 40-50% of cells underwent to apoptosis at 72 h after treatment. In contrast, a majority of Vaco 8/MGMT cells were stably accumulated in the G2/M phase of the cell cycle as long as 72 h after exposure to BG plus BCNU but not to . These results clearly demonstrate that in MGMT deficient cells, BCNU predominantly promotes apoptosis rather than G2 arrest regardless of the presence or absence of BG.
G2/M arrest was not initiated by DNA DSBs
DNA DSBs are considered to be the most relevant lesions causing G2/M arrest (Kaufmann and Kies, 1998). To test whether differential G2/M arrest in HCT116 and HCT116 BBR cells resulted from differential levels of DNA DSBs generated during the replication of DNA containing crosslink lesions induced by BCNU, pulsed-field gel electrophoresis (PFGE), an assay specifically to measure DNA DSBs, was performed in parallel with the analysis of regulation of cell cycle before and after treatments in these two cell lines. Results show that the levels of DNA DSBs induced by the treatment of BCNU alone were similar in both cell lines at 24 and 72 h, indicating that BCNU produces equivalent levels of DNA damage in these two cell lines. A significant increase in DNA DSBs was only observed in HCT116 cells at 72 h after exposure to the combination of BG with BCNU (Figure 5a, b) . Considering that B80% of HCT116 cells were already accumulated in G2/M at 24 h after BG and BCNU, the DNA DSBs appeared to not be the trigger initiating the onset of G2/ M checkpoint in response to BG plus BCNU. The significant induction of DNA DSBs formed at 72 h in HCT116 cells could be the consequence of damaged DNA attempting to be replicated in the absence of functional cell cycle checkpoints or cell division in an abnormal mitotic status. Studies have shown that DNA damage induced by irradiation, topoisomerase inhibitors, or hydroxyurea activate Chk1 (O'Connell et al., 1997; Liu et al., 2000) , and this activation is required for the initiation of G2 arrest in response to DNA damage through phosphorylating Cdc25C on Ser 216, a primary regulator proposed to be critical for G2 checkpoint regulation (Funari et al., 1997; Aguda, 1999) . Western blot analysis revealed that neither Chk1 nor p-Cdc25C (Ser 216) was significantly altered in response to DNA damage induced by BCNU alone or BG plus BCNU in both HCT116 and HCT116 BBR cell lines (Figure 6 ), suggesting that the G2/M arrest in HCT116 is not through the pathway of activation of Chk1 and Cdc25C. It has been demonstrated that following DNA damage, p53 transactivated p21 are the key characters mediating G2/M arrest and preventing mitotic entry (Cox and Lane, 1995; Sanchez et al., 1997; Taylor and Stark, 2001; Monte et al., 2003) . Therefore, it was of interest to check whether p53 could downregulate cyclin B1/Cdc2 activity via the induction of the CDK inhibitor p21 in order to induce G2/M arrest in response to BG plus BCNU. As shown in Figure 6 , after exposure either to BCNU alone or BG plus BCNU, the induction of p53 and p21 was observed over a period of 72 h in HCT116 cells, but remained constant in HCT116 BBR cells. To further determine whether p53 and p21 status was involved in G2/M arrest induced by BG and BCNU, we examined paired p53-mutant colon cancer cell lines, HCT15 and HCT15 BBR. A prolonged G2/M arrest ( Figure 7a ) accompanied by a concomitant increase in the levels of cyclin B1/p-Cdc2 (Tyr 15) (Figure 7b ) was only observed in HCT15 cells treated with BG plus BCNU, which is consistent with the results obtained from HCT116 cells. Accordingly, these results suggest that p53 and p21 may be involved in the regulation of cell cycle checkpoints after DNA damage in p53/p21 competent cells, but are not the sole determinants of prolonged G2/M arrest induced by BG plus BCNU.
Inhibition of mitotic entry resulted in prolonged G2/M arrest
It has been demonstrated that site-specific phosphorylation of core histone H3 at serine 10 appears to occur exclusively during mitosis in mammalian cells (Wei et al., 1999) . Thus, we used phospho-histone H3, a marker of mitosis, to determine the effect of BG plus BCNU on progression into mitosis. Mitotic content was quantitated from two-dimensional dot plots of DNA content versus phospho-histone H3 staining by flow cytometry. The results of representative experiments are shown in Figure 8a . In these experiments, the percentage of mitotic cells was measured relative to that detected in cells without treatment. As shown in Figure 8b , after a 24-h-treatment with BG plus BCNU, HCT116 cells showed a significant reduction of mitotic entry that was dramatically decreased to 19% of control value and the inhibition of the progression into mitosis was maintained up to 72 h, whereas there was no significant change of mitotic entry in the cells exposed to BCNU alone. In contrast, HCT116 BBR cells displayed slight increases in mitotic entry at the harvesting times analysed after BG plus BCNU. Mitotic cells stained with anti-phospho-histone H3 antibody revealed that 60% of mitotic cells detected in HCT116 cells treated with BG plus BCNU contained multiple spindle poles (Figure 9a ). Fluorescent images also demonstrated that in HCT116 cells after exposure to BG and BCNU, there was an increase in the number of multinucleated giant cells, which was correlated with the duration of cells arrested in G2/M in HCT116 cells (Figure 9b ). The percentages of multinucleated HCT116 cells treated with BG and BCNU were 1373.1, 3775.6 and 56712% at 24, 48 and 72 h, respectively, which were significantly higher than those maximally found in untreated cells (371.2%) or in BCNU only-treated cells (1275.3%). High percentage of multinucleated cells was also observed in HCT15 cells after arrested in G2/M by treatment with BG plus BCNU (Figure 9c ). In contrast, HCT116 BBR and HCT15 BBR cells were noted to maximally have 1574.0 and 1074.6% binucleated cell, respectively, at the tested times (24 and 72 h) after exposure to BG and BCNU, which might be the result of DNA replication being completed more than once in a single cell cycle with an overall increase in ploidy.
Inactivated wild-type MGMT by BG and BCNU but not K165E MGMT was required for initiation of prolonged G2/M checkpoint
In order to confirm whether inactivated wt MGMT by BG and BCNU but not K165E MGMT was required for initiation of prolonged G2/M checkpoint, we analysed cell cycle distribution in CHO cells that were transfected with wild-type MGMT and K165E MGMT cDNA, respectively. This was carried out to alleviate concerns that cell lines derived from tumors or after selection for drug resistance may have acquired uncharacterized genetic abnormalities that may confound the interpretation of the data obtained. In CHO-cell system after exposure to BCNU alone, CHO-wt MGMT showed a transient G2 arrest (B20-25% of the cell population arrested in G2) at 24 h; however, BG and BCNU accumulated 50-80% of cells in G2/M from 24 h through 72 h after treatment (Figure 10a ). In contrast, CHO-K165E MGMT cells displayed a similar cell cycle distribution in response to either BCNU alone or BG plus BCNU (Figure 10b ). Again, prolonged G2/M arrest was only observed in cells expressing wt MGMT after exposure to BG and BCNU.
Discussion
Two types of alterations of DNA structure appear to trigger the G2 checkpoint in response to chemotherapeutic agents: DNA DSBs induced by IR or etoposide, and chromosome catenation sustained by inhibition of topoisomerase II by the catalytic inhibitors of topoisomerase II, such as ICRF-193 that causes a mitotic delay in the absence of strand breaks (Lock, 1992; Poon et al., 1996; Kaufmann and Kies, 1998; Deming et al., 2001) . DNA damage-response checkpoints represent surveillance pathways that arrest damaged cells for DNA repair, resulting in cell survival and resistance to anticancer agents. The chromatid-catenation checkpoint assures that mitosis is not initiated until the intertwined daughter chromatids are sufficiently decatenated. Failures in either chekpoint pathway may lead to the development of polyploidy through aberrant mitosis. The findings presented here demonstrated that BG and BCNU induced a permanent G2/M arrest in HCT116 and that this arrest was not triggered by DNA DSBs, suggesting that it is a DNA replication checkpoint. Moreover, the pathway to initiate the prolonged G2/M delay in HCT116 was different from the DNA damage checkpoint pathway, which is activated through the activation of Chk1/p-Cdc25C (Ser 216) or p53/p21. Although we do not know what structures within the chromosomes induced by the combined treatment with BG plus BCNU are monitored by the checkpoint and Permanent G2/M arrest in response DNA damage L Yan et al these results suggest that distorted DNA structures induced by BCNU may be necessary for signaling G2/M arrest, but inactivated MGMT, probably through the post-translational modifications such as ubiquitination and phosphorylation, are needed to interact with other mitotic proteins to regulate mitosis. MGMT is well known and documented as a DNA repair protein. To date, the importance of this protein has been addressed by the action of repairing the alkylation lesions at the O 6 position of guanine and to cause resistance to alkylating therapeutic agents, such as BCNU. Thus, it seems to be unlikely that MGMT has other biological functions. Although whether or not MGMT is involved in a signaling pathway to regulate cell cycle or cell proliferation has not been fully explored yet, increasing evidence suggest the possibility that MGMT may act as a regulator or a mediator involved in the regulation of a signaling pathway. It has been shown that MGMT protein is phosphorylated at tyrosine, threonine, and serine residues and this phosphorylation is a regulatory mechanism for MGMT Srivenugopal et al., 2000) . It has also been demonstrated that this protein is highly susceptible to ubiquitination after exposure to BG plus BCNU (Srivenugopal et al., 1996) . Thus, it reasons to postulate that the status of phosphorylation or ubiquitination in wt MGMT induced by BG and BCNU may differ from those in K165 mutant MGMT, which may initiate different 'cross-talk' between proteins in the network of signal transduction through selecting specific proteins for activation or inactivation in order to control cell proliferation, cell cycle checkpoints and cell death (Vlach et al., 1997; Hochstrasser, 1998; Craig and Tyers, 1999) . How MGMT post-translational modifications are coordinated with the cell cycle checkpoints and the participation of cyclin B1/Cdc2 in G2/M arrest in response to BG and BCNU are unclear; however, these studies are currently underway in our laboratory.
Materials and methods

Cells lines and treatments
Paired isogenic cell lines (HCT116/HCT116 BBR and HCT15/ HCT15 BBR), except for the MGMT status, were used in this study. HCT116 BBR and HCT15 BBR cell lines were derived from HCT116 and HCT15 colon cancer cells that acquired different mutations at amino acid 165, in which lysine was substituted by glutamine (K165E in HCT116 BBR) and asparagine (K165N in HCT 15 BBR) after selection for resistance to BG and BCNU. The characteristics of these two MGMT-mutant cell lines are: (i) having a remaining repair capacity for alkylated adduct at O 6 -position of guanine; (ii) having a similar sensitivity to BCNU alone to their parental cell lines, and (iii) being highly resistant to inactivation of MGMT induced by BG (Liu et al., 2002) . HCT116/HCT116 BBR cells are p53 competent cells, and HCT15/HCT15 BBR cells are p53 deficient. In these studies, cells were treated consistently with BCNU (50 mM) and BG (50 mM) plus BCNU (50 mM) for all of the different experimental analyses.
Analysis of cell cycle distribution
Cells were fixed with 100% methanol and resuspended in a solution containing propidium iodide (PI, 20 mg/ml) and RNase (1 mg/ml) for 30 min. Cell cycle histograms were generated from analysis of PI-stained cells by flow cytometry.
Western blotting
After drug treatment, cells were pelleted by centrifugation, lysed in lysis buffer and briefly sonicated. Cellular protein content was quantified by the Bio-Rad assay. Equal amounts of protein (25 mg) were separated by SDS-PAGE and electrotransferred to PVDF membrane (Millipore Cor., Bedford, MA, USA). After blocking in TBS-T (0.05%) and 5% milk for 1 h at room temperature, the blots were incubated with primary antibody overnight at 41C. Sources of primary antibodies were as follows: Cyclin B1, Cdc2, p-Cdc2 (Tyr15), p53, p21 Chk1 and p-Cdc25c (Santa Cruz Biotechnology, CA, USA). Blots were incubated with horseradish peroxidaseconjugated secondary antibody and then visualized by enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Immunofluorescence microscopy
Cells were grown on coverslips and treated with BCNU alone or BG plus BCNU for 24, 48 and 72 h. Both treated and untreated cells were fixed in 2% paraformaldehyde and permeabilized with 0.2% Triton X-100. Cells were incubated with primary antibodies a-tubulin (Sigma, St Louis, MO, USA) or phospho-histone H3 (Upstate, Lake Placid, NY, USA) for detection of multinucleated and mitotic cells and then followed by secondary antibodies conjugated to Alexa 488 (green) (Molecular Probes). DAPI was used to stain cellular chromosomes. Images were digitally captured using an Olympus microscope equipped with a digital camera.
Mitotic cell determination
Mitotic cells were quantified via flow cytometric analysis of cells stained positive for the phospho-histone H3. Briefly, cells were harvested, washed with PBS, fixed with 2% paraformaldehyde in PBS and then permeabilized for 5 min with 0.05% Triton X-100 in PBS. Fixed cells were then labeled with primary anti-phospho-histone H3 and FITC-conjugated antirabbit IgG secondary antibodies (Upstate Bio-technology), followed by staining with PI.
Measurement of DNA DSBs by PFGE
A PFGE procedure was used to visualize induction of DNA DSBs. After exposure to BCNU or BG and BCNU, cells were harvested by scraping into ice-cold PBS. Cells were washed twice with ice-cold PBS, resuspended in an appropriate volume of PBS and an equal volume of 1.25% low melting point agarose in TBE buffer (89 mM Tris-HCl, pH 8.0, with 89 mM boric acid and 2 mM EDTA) to yield 5 Â 10 6 cells per 75 ml plug. The plugs were allowed to solidify on ice then were incubated at 501C overnight in approximately 5 ml of a lysis solution containing 1% sarcosyl, 100 mM EDTA, 10 mM TrisHCl, pH 7.5, and 100 mg/ml of proteinase K. The following day, the lysis solution was replaced with TE buffer (10 mM Tris-HCl, pH 7.5 with 50 mM EDTA). The plugs were incubated for 1 h at room temperature and the TE buffer was replaced for a day-long incubation, and then washed. Plugs were stored in TE buffer at 41C (Stamato and Denko, 1990).
The gel was prepared by placing the agarose plugs against the teeth of a comb. A solution of 0.8% agarose in TBE buffer was then poured around the comb and plugs. The comb was carefully removed before electrophoresis. The gel was run using a clamped homogeneous electric field (CHEF) Mapper XA system (BioRad, Hercules, CA, USA) using the following 1061 field inversion gel electrophoresis (FIGE) program-1500 s at 2.0 V/cm for 12 h, 1800 s at 2.0 V/cm for 24 h run at 41C.
After electrophoresis, the gel was stained with ethidium bromide to visualize DNA migration by UV fluorescence.
